Colossal Biosciences Said To Seek Fresh Capital At $20B–$30B Valuation

Colossal Biosciences, the Texas-based de-extinction startup, is exploring a new financing round that could value the company between $20 billion and $30 billion, according to people briefed on the talks. The five-year-old firm — which has already been priced at about $10.2 billion in earlier fundraising — has begun to record commercial income over the past year, though it’s unclear who would lead the planned round or how much money the company aims to raise.

Company founders have long argued the business can make money from several sources. Over the last year Colossal has pursued government and institutional work, pitching conservation and genetic tools to U.S. agencies and overseas partners; the United Arab Emirates committed roughly $60 million to the firm last year. The business has also deliberately turned parts of its platform into separate companies — a plastic-degradation startup, a computational biology service that raised $30 million, and an AI-driven modeling spinout that investors pegged at around $2 billion in March.

Colossal operates from a roughly 55,000-square-foot campus in Dallas and keeps expanding the list of species it targets for genetic restoration and conservation. The company added an African antelope species as its sixth candidate earlier this spring, and its philanthropic arm has signed a research pact with the University of Tasmania to tackle a contagious cancer afflicting Tasmanian devils. Executives have also flagged plans to commercialize an artificial animal gestation system, a technology they say could have eventual fertility applications for humans and is expected to reach maturity soon.

Investors appear to be pricing the startup as a platform business rather than simply a boutique conservation lab. One venture partner who follows biotech said the combination of government contracts, spinouts and productized tools could justify paying a premium — but cautioned that turning laboratory advances into steady, scalable revenue streams is difficult and time-consuming. Market momentum in longevity, energy alternatives and other capital-intensive science ventures has helped push valuations higher across the sector.

If Colossal succeeds in reintroducing species to the wild, the company has suggested it could monetize ecological benefits through tradable biodiversity credits, a concept modeled on carbon markets. Those projections remain contingent on long-term ecological outcomes and regulatory frameworks that are still being ironed out. For now, however, the firm’s reported move to seek a multibillion-dollar repricing reflects investor appetite for companies that can export genetic engineering and computational biology into multiple commercial channels.

Colossal did not respond to a request for comment about the fundraising conversations. Observers say the company’s next steps — who writes the checks, how large the round will be, and whether revenue growth can be sustained — will determine whether the new valuation range holds.